Sanofi (Sanofi) Institutional Ownership

: 5.22% (As of Today)

View and export this data going back to 2002. Start your Free Trial

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sanofi's institutional ownership is 5.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sanofi's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sanofi's Float Percentage Of Total Shares Outstanding is 0.00%.

Sanofi Institutional Ownership Historical Data

The historical data trend for Sanofi's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Historical Data

The historical data trend for Sanofi can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	5.39	5.36	3.07	5.30	5.29	5.30	5.27	5.22	5.23	5.22

Sanofi Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.